Oxford UK based Vaccitech reports positive topline interim data from a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
Vaccitech has signed a lease for 31,000 sq. ft at Harwell Science and Innovation Campus in the UK, fitting out the facility with a state-of-the art wet laboratory and offices.
